Compare FIP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | ARVN |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.0M | 658.2M |
| IPO Year | 2021 | 2018 |
| Metric | FIP | ARVN |
|---|---|---|
| Price | $4.49 | $9.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $11.00 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 1.0M | 697.6K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | 16.91 | ★ 58.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $502,520,000.00 | $262,600,000.00 |
| Revenue This Year | $58.19 | N/A |
| Revenue Next Year | $30.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 51.59 | N/A |
| 52 Week Low | $3.90 | $5.90 |
| 52 Week High | $7.93 | $14.22 |
| Indicator | FIP | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 33.96 |
| Support Level | $4.33 | $9.02 |
| Resistance Level | $6.34 | $10.18 |
| Average True Range (ATR) | 0.42 | 0.64 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 4.56 | 23.11 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.